About this file

This document is an amendment to a Request for Proposals (RFP) for a federal contract opportunity related to manufacturing and nonclinical studies support for the development of therapeutic biotechnology products (biologics) for neurological disorders.

The RFP, issued by the National Institutes of Health (NIH), seeks to add one or more contractors to an existing Indefinite Delivery/Indefinite Quantity (IDIQ) contract pool supporting this program. The contract has an ordering period that expires on September 29, 2030. The contractor shall provide current Good Manufacturing Practices (cGMP) manufacturing and Good Laboratory Practice (GLP) nonclinical services, including executing studies and completing documentation to enable regulatory filing and evaluation of biological therapeutics in clinical trials for NIH drug development programs. Key details include: a) clarification on DEA registration requirements, b) confirmation that certified cost or pricing data is not required, and c) the proposal submission deadline of July 8, 2024 at 2:00pm ET.

View the file

Other files

File Type Posted
Pre-Proposal Conference_Transcript.pdf PDF
Amendment 3_Questions and Responses_6.10.2024.pdf PDF
Pre-Proposal Conference_Slides.pptx PPTX presentation
Amendment 1_Questions and Responses_5.17.2024.pdf PDF
RFP Att. 17_SF-LLL.pdf PDF
RFP No. 75N95024R00050_Cover Letter.pdf PDF
RFP Att. 23_STO 3 - ASO Manufacturing Task Order.pdf PDF
RFP Att. 9_NIH 2043.pdf PDF
RFP Att. 10_HHS Subcontracting Plan Template.docx DOCX document
RFP Att. 24_STO 4 - BPN-Biologics PK and Tox Task Order.pdf PDF
RFP Att. 8_Additional Technical Proposal Instructions.pdf PDF
RFP Att. 22_STO 2 - AAV Manufacturing Task Order.pdf PDF
RFP Att. 3_IDIQ Contract SOW.pdf PDF
RFP Att. 1_Packaging and Delivery of Proposals.pdf PDF
RFP Att. 19_Invoice Instructions NIH(RC)2.pdf PDF
RFP Att. 18_Invoice Instructions NIH(RC)1.pdf PDF
RFP Att. 7_VAS Worksheet.pdf PDF
RFP Att. 5_Technical Proposal Cost Summary.pdf PDF
RFP Att. 15_Points-of-contact.pdf PDF
RFP Att. 14_Business Proposal Budget Template_TO_4.xlsx XLSX spreadsheet
RFP Att. 20_DEC Acknowledgment.pdf PDF
RFP Att. 2_Proposal Intent Response Form.pdf PDF
RFP Att. 11_Business Proposal Budget Template_TO_1.xlsx XLSX spreadsheet
RFP Att. 21_STO 1- Kickoff and Project Management Plan.pdf PDF
RFP Att. 16_Wage Rate Determination (2023).pdf PDF
RFP Att. 4_Section K RepsandCerts.pdf PDF
RFP Att. 12_Business Proposal Budget Template_TO_2.xlsx XLSX spreadsheet
RFP No. 75N95024R00050.pdf PDF
RFP Att. 6_Summary_of_Related_Activities.pdf PDF
RFP Att. 13_Business Proposal Budget Template_TO_3.xlsx XLSX spreadsheet
Show all 30

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

SOLICITATION QUESTIONS AND GOVERNMENT RESPONSES

May 17, 2024

QUESTION 1: In section M - Evaluation Factors for award there is a pass/fail table. Under part D, GLP compliance it states that we must provide the most recent FDA GLP inspection of our lab. We are capable of GLP work, and have completed GLP PK studies for other clients, but we have not been audited by the FDA. Is this going to prevent us from any possible award for this opportunity?

GOVERNMENT RESPONSE: If no audit has been conducted, please just state that no audit has been conducted. The offerors should understand that if an audit is conducted while on an NIH contract, a copy of the inspection report must be provided to NIH. The offerors should provide details on the compliance standards appropriate for the work they can perform and descriptions of past GLP-compliant work conducted in their proposal.

QUESTION 2: In the mandatory qualification criteria pass/fail table, can you clarify the DEA Research Registration requirement? Can we submit a response to this proposal while we are in the process of getting DEA registered? The final sentence of that criteria reads " In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule II-V controlled substances."

GOVERNMENT RESPONSE: Offerors who are in the process of obtaining a DEA Research Registration should provide details on the current timeline for getting registered. Any paperwork provided during the registration process can be offered as demonstration that the offeror is in the process of obtaining a DEA registration. All offerors should recognize that they will not be able to bid on work requiring a DEA registration if a current registration lapses or they are unable to obtain a DEA registration.

QUESTIONS 3: I would like to understand what is being asked from us. I didn’t see a specific project, with a specific molecule to write a proposal for. Pricing and timelines are dependent on knowing which molecule and what requirements are needed. Could you let me know when we will receive that information? Or what would be the next step?

GOVERNMENT RESPONSE: While responses related to the base contract should address all modalities that could potentially be handled, responses related to the sample task orders should be specific to the modality in that task order (i.e. AAV or ASO). The sample task orders include specific modalities which allows offerors to prepare a detailed response include pricing and timelines. Although they are sample task orders, responses related to the sample task orders should demonstrate the offeror’s approach and ability to handle the tasks outlined. Please see RFP Attachment 8, Additional Technical Proposal Instructions.

RFP No. 75N95024R00050 Amendment No. 2

May 31, 2024

QUESTION 4: If a subcontractor performing the nonclinical studies has AAALAC accreditation, will the AAALAC accreditation requirement as described in the proposal be satisfied? Is it a requirement that prime and the subcontractor each have their own AAALAC accreditation?

GOVERNMENT RESPONSE: All proposed animal facilities must have AAALAC accreditation. The prime is not required to have AAALAC accreditation if all animal facilities and activities using animals are in subcontracted facilities.

Please note: the prime contractor must have an OLAW Animal Welfare Assurance even if all animal facilities and activities using animals are in subcontracted facilities. In that case, an Interinstitutional Assurance is required. Please see the PHS Policy on Human Care and Use of Laboratory Animals at https://olaw.nih.gov/policies-laws/phs-policy.htm and information on Interinstitutional Assurances at https://olaw.nih.gov/resources/documents/interinstitutional-assurance.htm.

QUESTION 5: Please confirm that certified cost and pricing data is not required in accordance with FAR 15.403-1 as the Government is anticipating adequate competition, and this effort is anticipated to be under the $2,000,000 threshold delineated in FAR 15.403-4.

GOVERNMENT RESPONSE: Certified cost or pricing data is not required. FAR 15.403-4 states that certified cost or pricing data shall be obtained only if none of the exceptions in FAR 15.403-1(b) apply. An exception in FAR 15.403-1 applies and therefore certified cost or pricing data is not required.

QUESTION 6: Please confirm the due date for proposal submissions.

GOVERNMENT RESPONSE: The due date for proposal submissions is 2:00pm ET on July 8, 2024.

RFP No. 75N95024R00050 Amendment No. 2 https://olaw.nih.gov/policies-laws/phs-policy.htm https://olaw.nih.gov/resources/documents/interinstitutional-assurance.htm

File details come from the government source that posted it. Updated .